Agios Pharmaceuticals (FRA:8AP) Tax Provision: €0.87 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:8AP Agios Pharmaceuticals Inc FRA:8AP
44 GF Score
Price €35.40
GF Value €75.59
! 5 Warning Signs
View Full Analysis

What is Agios Pharmaceuticals Tax Provision?

Agios Pharmaceuticals FRA:8AP 44 Tax Provision is €0.87 Mil as of Mar. 2026. GuruFocus rates FRA:8AP with a GF Score™ of 44/100 and a GF Value™ of €75.59. The stock has 5 warning signs investors should review.

Agios Pharmaceuticals's tax provision for the three months ended in Mar. 2026 was €0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2026 was €0.87 Mil.

Agios Pharmaceuticals Tax Provision Historical Data

* Premium members only.

The historical data trend for Agios Pharmaceuticals's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Agios Pharmaceuticals Tax Provision Chart

Agios Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Tax Provision
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -42.25 0.87

Agios Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.87 0.00
FRA:8AP
44GF Score
Agios Pharmaceuticals Inc FRA:8AP
Tax Provision is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Agios Pharmaceuticals Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.87 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Provision →
What does a Tax Provision of €0.87 Mil mean?
Agios Pharmaceuticals (FRA:8AP) has a Tax Provision of €0.87 Mil as of Mar. 2026. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Agios Pharmaceuticals and its competitors.
Is Agios Pharmaceuticals' Tax Provision too high?
Agios Pharmaceuticals' current Tax Provision is €0.87 Mil. Overall, Agios Pharmaceuticals has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Agios Pharmaceuticals' Tax Provision compare to ABCL and KOD?
Agios Pharmaceuticals' Tax Provision of €0.87 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Provision for a Biotechnology company?
A good Tax Provision depends on the Biotechnology industry context. However, Tax Provision should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Provision mean?
A high Tax Provision can signal that a stock is expensive relative to its fundamentals. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Agios Pharmaceuticals and its competitors. Agios Pharmaceuticals's current Tax Provision is €0.87 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agios Pharmaceuticals stock overvalued right now?
Agios Pharmaceuticals (FRA:8AP) has a current Tax Provision of €0.87 Mil. The stock's GF Value™ is €75.59, compared to a current price of €35.40 — trading 53.2% below its estimated fair value. The current Tax Provision is €0.87 Mil. Agios Pharmaceuticals' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Provision calculated?
Tax Provision is calculated from a company's financial statements. For Agios Pharmaceuticals (FRA:8AP), the current Tax Provision is €0.87 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Agios Pharmaceuticals (FRA:8AP) Overvalued in 2026?

Based on GuruFocus' analysis, Agios Pharmaceuticals stock appears to be undervalued. The current stock price of €35.40 is trading 53.2% below its estimated GF Value™ of €75.59.

Key valuation signals for FRA:8AP:

  • Tax Provision: €0.87 Mil
  • GF Value™: €75.59 vs. price of €35.40 (53.2% below fair value)
  • GF Score™: 44/100 with 5 warning signs

No single metric tells the full story. See the FRA:8AP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Agios Pharmaceuticals Business Description

Other Exchanges AGIO:USA0HB0:UK8AP:Germany
Address 88 Sidney Street, Cambridge, MA, USA, 02139
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
44GF Score

Get the complete analysis for FRA:8AP

Tax Provision is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€35.40
Price
€75.59
GF Value